METHODS OF NORMALIZING MEASURED DRUG CONCENTRATIONS AND TESTING FOR NON-COMPLIANCE WITH A DRUG TREATMENT REGIMEN

• US 20110195520A1
• Filed: 02/11/2010
• Published: 08/11/2011
• Est. Priority Date: 02/11/2010
• Status: Abandoned Application

• Current Assignee: Ameritox Limited (Aegis Sciences Corporation)
• Original Assignee: Ameritox Limited (Aegis Sciences Corporation)
• Inventors: Leider, Harry, Linden, Ariel
• Application Number:
  US12/704,169
• Publication Number:
  US 20110195520A1
• Time in Patent Office: Days
• US Class Current: 436/501
• CPC Class Codes: G01N 33/9486 Analgesics, e.g. opiates, aspirine

Abstract

Methods for monitoring subject compliance with a prescribed treatment regimen are disclosed. In one embodiment, the method comprises measuring a drug level in fluid of a subject and normalizing said measured drug level as a function of one or more parameters associated with the subject. The normalized drug level is compared to a reference value and associated confidence intervals or to a concentration range. The reference value and associated confidence intervals and/or the concentration range may be normalized based on one or more parameters associated with subjects in a reference population.

Claims

1. A method of detecting non-compliance with a prescribed opioid regimen in a subject, comprising:

(a) providing a subject that is prescribed a daily dose of said opioid;

(b) determining a normalized level of said opioid in fluid of the subject;

(c) developing, in a population that does not include said subject, normalized reference opioid levels and confidence intervals corresponding to each of a plurality of daily doses of said opioid;

(d) comparing the normalized level of said opioid in the fluid of said subject to the normalized reference opioid level corresponding to the prescribed daily dose of said opioid;

(e) identifying the subject as non-compliant if the normalized level of said opioid in the fluid of said subject falls outside the confidence interval determined in step (c) corresponding to the subject'"'"'s prescribed daily dose.

2. The method of claim 1 wherein the opioid is selected from codeine, morphine, thebaine, oripavine, diacetylmorphine, dihydrocodeine, hydrocodone, hydromorphone, nicomorphone, oxycodone, oxymorphone, fentanyl, alphamethylfentanyl, alfentanil, sufentanil, remifentanil, carfentanyl, ohmefentanyl, pethidine, keobemidone, desmethylprodine, (MPPP), allylprodine, prodine, 4-phenyl-1-(2-phenylethyl)piperidin-4-yl acetate (PEPAP), propoxyphene, dextropropoxyphene, dextromoramide, bezitramide, piritramide, methadone, dipipanone, levomathadyl acetate (LAAM), difenoxin, diphenoxylate, loperamide, dezocine, pentazocine, phenazocine, buprenorphine, dihydroetorphine, etorphine, butorphanol, nalbuphine, levorphanol, levomethorphan, lefetamine, meptazinol, tilidine, tramadol, tapentadol, nalmefene, naloxone, naltrexone, methadone, oxazepam, lorazepam, alprazolam, diazepam, and combinations thereof.

3. The method of claim 2 wherein the opioid comprises oxycodone.

4. The method of claim 3 wherein the oxycodone is controlled-release oxycodone.

5. The method of claim 3 wherein the level of oxycodone is determined at least 24 hours after said subject initiates said daily dose of oxycodone.

6. The method of claim 3 wherein the level of oxycodone is determined at least 36 hours after said subject initiates said daily dose of oxycodone.

7. The method of claim 3 wherein the level of oxycodone is determined at least 48 hours after said subject initiates said daily dose of oxycodone.

8. The method of claim 3 wherein the level of oxycodone is determined at least 72 hours after said subject initiates said daily dose of oxycodone.

9. The method of claim 1 wherein the level of said opioid is determined using LC-MS-MS or GC-MS-MS.

10. The method of claim 1 wherein the level of said opioid is normalized prior to step (d).

11. The method of claim 1 wherein the level of said opioid is normalized as a function of one or more of fluid pH, fluid specific gravity, fluid creatinine concentration, subject height, subject weight, subject age, subject body mass index, subject gender, subject lean body mass, and subject body surface area.

12. The method of claim 1 wherein the normalized level of said opioid is by the equation:

[N]=[C]×

((SG_N−

1.00)/(SG−

1.00),

where [N] is the normalized level, [C] is a raw drug concentration measured in fluid of the subject, SG_N is a normalized specific gravity value associated with fluid of the same type as the fluid of the subject, and SG is a specific gravity value associated with the fluid of the subject.

13. The method of claim 1 wherein the level of said opioid is normalized according to the equation:

[N]=[C]×

((SG_N−

1.00)/(SG−

1.00))×

(LBW/122)×

(pH/8.5)^0.56,

where [N] is the normalized level, [C] is a raw drug concentration measured in fluid of the subject, SG_N is a normalized specific gravity value associated with fluid of the same type as the fluid of the subject, SG is a specific gravity value associated with the fluid of the subject, LBW is a lean body weight value associated with the subject, and pH is a pH value of the fluid of the subject.

14. The method of claim 1 wherein the opioid is oxycodone, the fluid is urine, and the level of oxycodone is normalized according to the equation:

[N]=[C]×

((0.03)/(SG−

1.00))×

(LBW/122)×

(pH/8.5)^0.56,

where [N] is the normalized level of oxycodone, [C] is a total raw concentration of oxycodone and at least one of oxymorphone and noroxycodone measured in urine of the subject, SG is a specific gravity value associated with the urine of the subject, LBW is a lean body weight value associated with the subject, and pH is a pH value of the urine of the subject.

15. The method of claim 1 wherein the level of said opioid is normalized according to the equation:

[N]=[C]×

((CR_N−

1.00)/(CR−

1.00),

where [N] is the normalized level, [C] is a raw drug concentration measured in fluid of the subject, CR_N is a normalized creatinine concentration value associated with fluid of the same type as the fluid of the subject, and CR is a creatinine value associated with the fluid of the subject.

16. The method of claim 1 wherein the fluid is one or more of urine, blood, or plasma.

17. The method of claim 1 wherein the fluid is urine.

18. The method of claim 1 wherein the level of said opioid in fluid of said subject is determined after said opioid has reached a steady state in said subject.

19. The method of claim 1 wherein the level of said opioid in fluid of said subject is determined after a time sufficient for said level to achieve a steady state.

20. The method of claim 1 wherein the level of said opioid is a steady state level.

21. The method of claim 1 wherein the secondary population comprises about 1 to about 1000 subjects.

22. The method of claim 1 wherein the normalized reference opioid levels corresponding to each of said plurality of daily opioid doses are determined by:

(i) assigning each of the subjects to one of the plurality of daily doses, (ii) administering the assigned daily dose to each of the subjects until steady state is achieved;

(iii) measuring raw opioid levels in fluid of a plurality of the subjects;

(iv) normalizing the raw opioid levels for fluid pH, fluid specific gravity, and lean body mass to produce normalized fluid opioid levels;

(v) determining median estimates of the normalized fluid opioid levels corresponding to each of the plurality of daily doses of said opioid; and

(vi) determining upper and lower confidence intervals for each of said normalized median estimates.

23. The method of claim 22 wherein the upper and lower confidence intervals corresponding to a first normalized median estimate corresponding to one of the plurality of daily opioid doses does not overlap with a second normalized median estimate corresponding to a second of the plurality of daily opioid doses.

24. The method of claim 22 wherein the upper and lower confidence intervals are developed using a Bonnet-Price statistical method.

25. A method of detecting non-compliance with a prescribed opioid regimen in a subject, comprising:

(a) identifying a subject'"'"'s prescribed daily dose of said opioid;

(b) determining a steady state level of said opioid in urine of the subject;

(c) normalizing said steady state level as a function of one or more parameters associated with the subject;

(d) developing, in a secondary population that does not include said subject, normalized confidence intervals for urine opioid levels corresponding to each of a plurality of daily doses of said opioid;

(e) comparing the normalized steady state level of said opioid in the urine of said subject to the normalized confidence intervals corresponding to each of said plurality of daily opioid doses; and

(f) identifying the subject as non-compliant if the determined steady state level of said opioid in the urine of said subject does not fall within the normalized confidence intervals corresponding to the subject'"'"'s prescribed daily dose.

26. The method of claim 25 wherein a plurality of members are assigned to the secondary population based on the presence or absence of one or more exclusion criteria.

27. The method of claim 26 wherein the one or more exclusion criteria are selected from the list comprising CYP2D6 allele variation, histories of substance abuse;

significant disease;

recent illness;

abnormal findings on physical examination, electrocardiogram, laboratory studies, or drug screens;

recent history of prescription drug use, over-the-counter drug use, or herbal drug use;

allergies or hypersensitivities to naltrexone, opioids, or similar compounds;

recent history of use of alcohol, ingestion of grapefruit, ingestion of grapefruit juice, ingestion of caffeine, or ingestion of xanthene-containing products; and

participation in another drug therapy or opioid-related clinical trial or study.

28. The method of claim 25 wherein the secondary population includes no members with a non-functional CYP2D6 allele.

29. The method of claim 25 wherein the secondary population includes no members with a reduced-function CYP2D6 allele.

30. The method of claim 25 wherein the secondary population includes no members with a non-functional or a reduced-function CYP2D6 allele.

31. The method of claim 25 wherein the secondary population is essentially comprised of members with a functional CYP2D6 allele.

32. The method of claim 25 wherein the steady state level of said opioid is determined using LC-MS-MS or GC-MS-MS.

33. A method of determining a subject'"'"'s non-compliance with a prescribed treatment protocol comprising:

measuring a drug concentration in fluid of the subject;

measuring one or more parameters associated with the subject;

calculating a normalized drug concentration for the subject as a function of the drug concentration and the one or more measured parameters;

developing, in a population that does not include the subject, a normalized reference drug concentration range corresponding to the prescribed treatment protocol;

comparing the normalized drug concentration of the subject to the normalized reference drug concentration range; and

determining that the subject is non-compliant if the normalized drug concentration of the subject falls outside of the normalized reference drug concentration range.

34. The method of claim 33 wherein the drug concentration is a steady state drug concentration.

35. The method of claim 33 wherein the drug concentration is measured using LC-MS-MS or GC-MS-MS.

36. The method of claim 33 wherein the fluid is selected from urine, blood, or plasma.

37. The method of claim 33 wherein the one or more parameters is selected from the group consisting of urine pH, urine specific gravity, urine creatinine concentration, subject height, subject weight, subject age, subject body mass index, subject gender, subject lean body mass, and subject body surface area.

38. The method of claim 33 wherein the one or more parameters comprise urine pH, urine specific gravity, subject weight, subject gender, and subject height.

39. The method of claim 33 wherein the one or more parameters comprise urine pH, urine specific gravity, and subject lean body mass.

40. The method of claim 33 wherein the drug comprises an opioid.

41. The method of claim 40 wherein the opioid comprises oxycodone.

42. The method of claim 40 wherein the opioid comprises controlled-release oxycodone.

43. The method of claim 40 wherein the opioid comprises a metabolite of oxycodone.

44. A method of confirming a subject'"'"'s non-adherence to a chronic opioid therapy regimen comprising:

prescribing to the subject a chronic opioid therapy regimen, said regimen comprising a daily dose of an opioid;

determining, after a time sufficient to achieve steady state, an opioid concentration in the subject;

normalizing said opioid concentration;

developing, in a secondary population that does not include the subject, a normalized opioid range corresponding to the prescribed daily dose of the opioid;

comparing the normalized opioid concentration in the subject to the normalized opioid range corresponding to the prescribed daily dose of the opioid; and

determining the subject'"'"'s non-adherence to the chronic opioid therapy regimen if the normalized opioid concentration in the subject falls outside the confidence intervals corresponding to the prescribed daily dose of the opioid.

45. The method of claim 44 wherein the normalized opioid concentration is based on a raw opioid concentration measured by LC-MS-MS or GC-MS-MS.

46. The method of claim 44 wherein the opioid comprises oxycodone.

47. The method of claim 44 wherein the opioid comprises controlled-release oxycodone.

48. The method of claim 44 wherein the opioid comprises a metabolite of oxycodone.

49. The method of claim 44 wherein a plurality of members are assigned to the secondary population based on the presence or absence of one or more exclusion criteria.

50. The method of claim 49 wherein the one or more exclusion criteria are selected from the list comprising CYP2D6 allele variation, histories of substance abuse;

significant disease;

recent illness;

abnormal findings on physical examination, electrocardiogram, laboratory studies, or drug screens;

recent history of prescription drug use, over-the-counter drug use, or herbal drug use;

allergies or hypersensitivities to naltrexone, opioids, or similar compounds;

recent history of use of alcohol, ingestion of grapefruit, ingestion of grapefruit juice, ingestion of caffeine, or ingestion of xanthene-containing products; and

participation in another drug therapy or opioid-related clinical trial or study.

51. The method of claim 44 wherein the secondary population includes no members with a non-functional CYP2D6 allele.

52. The method of claim 44 wherein the secondary population includes no members with a reduced-function CYP2D6 allele.

53. The method of claim 44 wherein the secondary population includes no members with a non-functional or a reduced-function CYP2D6 allele.

54. The method of claim 44 wherein the secondary population is essentially comprised of members with functional CYP2D6 alleles.

55. The method of claim 44 wherein the normalized opioid concentration in the subject is determined by:

measuring a steady state opioid concentration in urine of the subject;

measuring one or more parameters in the subject and/or urine of the subject; and

calculating the normalized opioid concentration in the subject as a function of the one or more parameters measured in the subject and/or urine of the subject.

56. The method of claim 55 wherein the steady state opioid concentration is measured using LC-MS-MS or GC-MS-MS.

57. The method of claim 55 wherein the one or more parameters are selected from the group consisting of urine pH, urine specific gravity, urine creatinine concentration, subject height, subject weight, subject age, subject body mass index, subject gender, subject lean body mass, and subject body surface area.

58. The method of claim 55 wherein the one or more parameters comprise urine pH, urine specific gravity, subject weight, subject gender, and subject height.

59. The method of claim 55 wherein the one or more parameters comprise urine pH, urine specific gravity, and subject lean body mass.

60. The method of claim 55 wherein the subject has a high risk of aberrant drug-related behavior.

61. The method of claim 55 wherein the subject has a history of aberrant drug-related behavior.